No change in apolipoprotein AI metabolism when subcutaneous insulin infusion is replaced by intraperitoneal insulin infusion in type 1 diabetic patients
Abstract In type 1 diabetic patients, the replacement of subcutaneous insulin infusion by intraperitoneal insulin infusion restores the normal physiological gradient between the portal vein and the peripheral circulation, which is likely to modify HDL metabolism. This stable isotope kinetic study wa...
Gespeichert in:
| Veröffentlicht in: | Atherosclerosis 2007-10, Vol.194 (2), p.342-347 |
|---|---|
| Hauptverfasser: | , , , , , , , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 347 |
|---|---|
| container_issue | 2 |
| container_start_page | 342 |
| container_title | Atherosclerosis |
| container_volume | 194 |
| creator | Duvillard, Laurence Florentin, Emmanuel Baillot-Rudoni, Sabine Lalanne-Mistrich, Marie-Laure Brun-Pacaud, Agnès Petit, Jean-Michel Brun, Jean-Marcel Gambert, Philippe Vergès, Bruno |
| description | Abstract In type 1 diabetic patients, the replacement of subcutaneous insulin infusion by intraperitoneal insulin infusion restores the normal physiological gradient between the portal vein and the peripheral circulation, which is likely to modify HDL metabolism. This stable isotope kinetic study was designed to compare HDL apolipoprotein (apo) AI metabolism in seven type 1 diabetic patients first treated by continuous subcutaneous insulin infusion by an external pump and then 3 months after the beginning of intraperitoneal insulin infusion by an implantable pump. Glycaemic control was comparable under subcutaneous and intraperitoneal insulin infusion (HbA1c = 7.34 ± 0.94% versus 7.24 ± 1.00%, NS). HDL composition was similar under both insulin regimens (esterified cholesterol = 20.1 ± 2.5% versus 24.0 ± 3.0% (NS), free cholesterol = 3.4 ± 1.1% versus 3.3 ± 0.9% (NS), triglycerides = 2.4 ± 0.9% versus 2.1 ± 0.9% (NS), phospholipids = 22.7 ± 5.3% versus 25.2 ± 6.5% (NS) and proteins = 51.2 ± 6.3% versus 45.5 ± 4.7% (NS)). The replacement of subcutaneous insulin infusion by intraperitoneal insulin infusion induced significant changes neither in apoAI fractional catabolic rate, nor in apoAI production rate, nor in apoAI pool size (respectively, 0.199 ± 0.051 pool d−1 versus 0.211 ± 0.017 pool d−1 , 12.0 ± 3.2 mg kg−1 d−1 versus 12.1 ± 1.8 mg kg−1 d−1 , 60.4 ± 5.0 mg kg−1 versus 57.5 ± 7.5 mg kg−1 ). In conclusion, HDL metabolism is not modified by the replacement of subcutaneous insulin infusion by intraperitoneal insulin infusion when glycaemia is well controlled under both insulin regimens. As far as HDL metabolism is concerned there is no advantage in favour of one way of insulin administration or another. |
| doi_str_mv | 10.1016/j.atherosclerosis.2006.10.034 |
| format | Article |
| fullrecord | <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_68424364</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><els_id>S002191500600671X</els_id><sourcerecordid>68424364</sourcerecordid><originalsourceid>FETCH-LOGICAL-c472t-fd51d0eb532cb3c3d87ea8c77d16cb45b9ef3e29cbaa0c39dcee7655e8a5a39f3</originalsourceid><addsrcrecordid>eNqNkt-K1DAUxoMo7rj6CpKb9a5j0qRNe6GwLLouLHqhgnchSU-djG1Tk1SZN9nH3VNmUFi8EEL-_s5J8n2HkAvOtpzx-vV-a_IOYkhuWHuftiVjNZ5tmZCPyIY3qi24bORjsmGs5EXLK3ZGnqW0Z4xJxZun5IwrLrlqqg25-xio25npO1A_UTOHwc9hjiEDLi9v6AjZWNxMI_29g4mmxbolmwnCkjAiLQNyfuqX5ANOEo0wD8ZBR-0B93M0M0SfwwRm-Ac_0XyYgXLaeWMhe0dnkz1MOT0nT3ozJHhxGs_J1_fvvlx9KG4_Xd9cXd4WTqoyF31X8Y6BrUTprHCiaxSYxinV8dpZWdkWegFl66wxzIm2cwCqripoTGVE24tz8uqYFz_9c4GU9eiTg2E4_lHXjSylqCWCb46gQ9lThF7P0Y8mHjRnerVG7_UDa_RqzXqM1mD8y9NFix2h-xt98gKBixNgkjNDH83kMMcfruWqrBuG3PWRA5Tll4eok0PJUHMfwWXdBf_fT3r7IJNDezxe_gMOkPZhiRNqr7lOpWb681pPazmxGpvi38Q9m4zRPA</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>68424364</pqid></control><display><type>article</type><title>No change in apolipoprotein AI metabolism when subcutaneous insulin infusion is replaced by intraperitoneal insulin infusion in type 1 diabetic patients</title><source>MEDLINE</source><source>Elsevier ScienceDirect Journals</source><creator>Duvillard, Laurence ; Florentin, Emmanuel ; Baillot-Rudoni, Sabine ; Lalanne-Mistrich, Marie-Laure ; Brun-Pacaud, Agnès ; Petit, Jean-Michel ; Brun, Jean-Marcel ; Gambert, Philippe ; Vergès, Bruno</creator><creatorcontrib>Duvillard, Laurence ; Florentin, Emmanuel ; Baillot-Rudoni, Sabine ; Lalanne-Mistrich, Marie-Laure ; Brun-Pacaud, Agnès ; Petit, Jean-Michel ; Brun, Jean-Marcel ; Gambert, Philippe ; Vergès, Bruno</creatorcontrib><description>Abstract In type 1 diabetic patients, the replacement of subcutaneous insulin infusion by intraperitoneal insulin infusion restores the normal physiological gradient between the portal vein and the peripheral circulation, which is likely to modify HDL metabolism. This stable isotope kinetic study was designed to compare HDL apolipoprotein (apo) AI metabolism in seven type 1 diabetic patients first treated by continuous subcutaneous insulin infusion by an external pump and then 3 months after the beginning of intraperitoneal insulin infusion by an implantable pump. Glycaemic control was comparable under subcutaneous and intraperitoneal insulin infusion (HbA1c = 7.34 ± 0.94% versus 7.24 ± 1.00%, NS). HDL composition was similar under both insulin regimens (esterified cholesterol = 20.1 ± 2.5% versus 24.0 ± 3.0% (NS), free cholesterol = 3.4 ± 1.1% versus 3.3 ± 0.9% (NS), triglycerides = 2.4 ± 0.9% versus 2.1 ± 0.9% (NS), phospholipids = 22.7 ± 5.3% versus 25.2 ± 6.5% (NS) and proteins = 51.2 ± 6.3% versus 45.5 ± 4.7% (NS)). The replacement of subcutaneous insulin infusion by intraperitoneal insulin infusion induced significant changes neither in apoAI fractional catabolic rate, nor in apoAI production rate, nor in apoAI pool size (respectively, 0.199 ± 0.051 pool d−1 versus 0.211 ± 0.017 pool d−1 , 12.0 ± 3.2 mg kg−1 d−1 versus 12.1 ± 1.8 mg kg−1 d−1 , 60.4 ± 5.0 mg kg−1 versus 57.5 ± 7.5 mg kg−1 ). In conclusion, HDL metabolism is not modified by the replacement of subcutaneous insulin infusion by intraperitoneal insulin infusion when glycaemia is well controlled under both insulin regimens. As far as HDL metabolism is concerned there is no advantage in favour of one way of insulin administration or another.</description><identifier>ISSN: 0021-9150</identifier><identifier>EISSN: 1879-1484</identifier><identifier>DOI: 10.1016/j.atherosclerosis.2006.10.034</identifier><identifier>PMID: 17141785</identifier><language>eng</language><publisher>Amsterdam: Elsevier Ireland Ltd</publisher><subject>Administration, Cutaneous ; Adult ; Apolipoprotein A-I - drug effects ; Apolipoprotein A-I - metabolism ; Apolipoprotein AI ; Associated diseases and complications ; Atherosclerosis (general aspects, experimental research) ; Biological and medical sciences ; Blood and lymphatic vessels ; Carbon Compounds, Inorganic ; Cardiology. Vascular system ; Cardiovascular ; Cardiovascular system ; Diabetes Mellitus, Type 1 - drug therapy ; Diabetes Mellitus, Type 1 - metabolism ; Diabetes. Impaired glucose tolerance ; Endocrine pancreas. Apud cells (diseases) ; Endocrinopathies ; External pump ; Female ; HDL ; Humans ; Implantable pump ; Infusions, Parenteral ; Insulin ; Insulin - administration & dosage ; Insulin Infusion Systems ; Kinetic study ; Kinetics ; Lipoproteins, HDL - drug effects ; Lipoproteins, HDL - metabolism ; Male ; Medical sciences ; Middle Aged ; Pharmacology. Drug treatments ; Sulfides ; Type 1 diabetes mellitus ; Vasodilator agents. Cerebral vasodilators</subject><ispartof>Atherosclerosis, 2007-10, Vol.194 (2), p.342-347</ispartof><rights>Elsevier Ireland Ltd</rights><rights>2006 Elsevier Ireland Ltd</rights><rights>2008 INIST-CNRS</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c472t-fd51d0eb532cb3c3d87ea8c77d16cb45b9ef3e29cbaa0c39dcee7655e8a5a39f3</citedby><cites>FETCH-LOGICAL-c472t-fd51d0eb532cb3c3d87ea8c77d16cb45b9ef3e29cbaa0c39dcee7655e8a5a39f3</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktohtml>$$Uhttps://www.sciencedirect.com/science/article/pii/S002191500600671X$$EHTML$$P50$$Gelsevier$$H</linktohtml><link.rule.ids>314,776,780,3536,27903,27904,65309</link.rule.ids><backlink>$$Uhttp://pascal-francis.inist.fr/vibad/index.php?action=getRecordDetail&idt=19172680$$DView record in Pascal Francis$$Hfree_for_read</backlink><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/17141785$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Duvillard, Laurence</creatorcontrib><creatorcontrib>Florentin, Emmanuel</creatorcontrib><creatorcontrib>Baillot-Rudoni, Sabine</creatorcontrib><creatorcontrib>Lalanne-Mistrich, Marie-Laure</creatorcontrib><creatorcontrib>Brun-Pacaud, Agnès</creatorcontrib><creatorcontrib>Petit, Jean-Michel</creatorcontrib><creatorcontrib>Brun, Jean-Marcel</creatorcontrib><creatorcontrib>Gambert, Philippe</creatorcontrib><creatorcontrib>Vergès, Bruno</creatorcontrib><title>No change in apolipoprotein AI metabolism when subcutaneous insulin infusion is replaced by intraperitoneal insulin infusion in type 1 diabetic patients</title><title>Atherosclerosis</title><addtitle>Atherosclerosis</addtitle><description>Abstract In type 1 diabetic patients, the replacement of subcutaneous insulin infusion by intraperitoneal insulin infusion restores the normal physiological gradient between the portal vein and the peripheral circulation, which is likely to modify HDL metabolism. This stable isotope kinetic study was designed to compare HDL apolipoprotein (apo) AI metabolism in seven type 1 diabetic patients first treated by continuous subcutaneous insulin infusion by an external pump and then 3 months after the beginning of intraperitoneal insulin infusion by an implantable pump. Glycaemic control was comparable under subcutaneous and intraperitoneal insulin infusion (HbA1c = 7.34 ± 0.94% versus 7.24 ± 1.00%, NS). HDL composition was similar under both insulin regimens (esterified cholesterol = 20.1 ± 2.5% versus 24.0 ± 3.0% (NS), free cholesterol = 3.4 ± 1.1% versus 3.3 ± 0.9% (NS), triglycerides = 2.4 ± 0.9% versus 2.1 ± 0.9% (NS), phospholipids = 22.7 ± 5.3% versus 25.2 ± 6.5% (NS) and proteins = 51.2 ± 6.3% versus 45.5 ± 4.7% (NS)). The replacement of subcutaneous insulin infusion by intraperitoneal insulin infusion induced significant changes neither in apoAI fractional catabolic rate, nor in apoAI production rate, nor in apoAI pool size (respectively, 0.199 ± 0.051 pool d−1 versus 0.211 ± 0.017 pool d−1 , 12.0 ± 3.2 mg kg−1 d−1 versus 12.1 ± 1.8 mg kg−1 d−1 , 60.4 ± 5.0 mg kg−1 versus 57.5 ± 7.5 mg kg−1 ). In conclusion, HDL metabolism is not modified by the replacement of subcutaneous insulin infusion by intraperitoneal insulin infusion when glycaemia is well controlled under both insulin regimens. As far as HDL metabolism is concerned there is no advantage in favour of one way of insulin administration or another.</description><subject>Administration, Cutaneous</subject><subject>Adult</subject><subject>Apolipoprotein A-I - drug effects</subject><subject>Apolipoprotein A-I - metabolism</subject><subject>Apolipoprotein AI</subject><subject>Associated diseases and complications</subject><subject>Atherosclerosis (general aspects, experimental research)</subject><subject>Biological and medical sciences</subject><subject>Blood and lymphatic vessels</subject><subject>Carbon Compounds, Inorganic</subject><subject>Cardiology. Vascular system</subject><subject>Cardiovascular</subject><subject>Cardiovascular system</subject><subject>Diabetes Mellitus, Type 1 - drug therapy</subject><subject>Diabetes Mellitus, Type 1 - metabolism</subject><subject>Diabetes. Impaired glucose tolerance</subject><subject>Endocrine pancreas. Apud cells (diseases)</subject><subject>Endocrinopathies</subject><subject>External pump</subject><subject>Female</subject><subject>HDL</subject><subject>Humans</subject><subject>Implantable pump</subject><subject>Infusions, Parenteral</subject><subject>Insulin</subject><subject>Insulin - administration & dosage</subject><subject>Insulin Infusion Systems</subject><subject>Kinetic study</subject><subject>Kinetics</subject><subject>Lipoproteins, HDL - drug effects</subject><subject>Lipoproteins, HDL - metabolism</subject><subject>Male</subject><subject>Medical sciences</subject><subject>Middle Aged</subject><subject>Pharmacology. Drug treatments</subject><subject>Sulfides</subject><subject>Type 1 diabetes mellitus</subject><subject>Vasodilator agents. Cerebral vasodilators</subject><issn>0021-9150</issn><issn>1879-1484</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2007</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><recordid>eNqNkt-K1DAUxoMo7rj6CpKb9a5j0qRNe6GwLLouLHqhgnchSU-djG1Tk1SZN9nH3VNmUFi8EEL-_s5J8n2HkAvOtpzx-vV-a_IOYkhuWHuftiVjNZ5tmZCPyIY3qi24bORjsmGs5EXLK3ZGnqW0Z4xJxZun5IwrLrlqqg25-xio25npO1A_UTOHwc9hjiEDLi9v6AjZWNxMI_29g4mmxbolmwnCkjAiLQNyfuqX5ANOEo0wD8ZBR-0B93M0M0SfwwRm-Ac_0XyYgXLaeWMhe0dnkz1MOT0nT3ozJHhxGs_J1_fvvlx9KG4_Xd9cXd4WTqoyF31X8Y6BrUTprHCiaxSYxinV8dpZWdkWegFl66wxzIm2cwCqripoTGVE24tz8uqYFz_9c4GU9eiTg2E4_lHXjSylqCWCb46gQ9lThF7P0Y8mHjRnerVG7_UDa_RqzXqM1mD8y9NFix2h-xt98gKBixNgkjNDH83kMMcfruWqrBuG3PWRA5Tll4eok0PJUHMfwWXdBf_fT3r7IJNDezxe_gMOkPZhiRNqr7lOpWb681pPazmxGpvi38Q9m4zRPA</recordid><startdate>20071001</startdate><enddate>20071001</enddate><creator>Duvillard, Laurence</creator><creator>Florentin, Emmanuel</creator><creator>Baillot-Rudoni, Sabine</creator><creator>Lalanne-Mistrich, Marie-Laure</creator><creator>Brun-Pacaud, Agnès</creator><creator>Petit, Jean-Michel</creator><creator>Brun, Jean-Marcel</creator><creator>Gambert, Philippe</creator><creator>Vergès, Bruno</creator><general>Elsevier Ireland Ltd</general><general>Elsevier</general><scope>IQODW</scope><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7X8</scope></search><sort><creationdate>20071001</creationdate><title>No change in apolipoprotein AI metabolism when subcutaneous insulin infusion is replaced by intraperitoneal insulin infusion in type 1 diabetic patients</title><author>Duvillard, Laurence ; Florentin, Emmanuel ; Baillot-Rudoni, Sabine ; Lalanne-Mistrich, Marie-Laure ; Brun-Pacaud, Agnès ; Petit, Jean-Michel ; Brun, Jean-Marcel ; Gambert, Philippe ; Vergès, Bruno</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c472t-fd51d0eb532cb3c3d87ea8c77d16cb45b9ef3e29cbaa0c39dcee7655e8a5a39f3</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2007</creationdate><topic>Administration, Cutaneous</topic><topic>Adult</topic><topic>Apolipoprotein A-I - drug effects</topic><topic>Apolipoprotein A-I - metabolism</topic><topic>Apolipoprotein AI</topic><topic>Associated diseases and complications</topic><topic>Atherosclerosis (general aspects, experimental research)</topic><topic>Biological and medical sciences</topic><topic>Blood and lymphatic vessels</topic><topic>Carbon Compounds, Inorganic</topic><topic>Cardiology. Vascular system</topic><topic>Cardiovascular</topic><topic>Cardiovascular system</topic><topic>Diabetes Mellitus, Type 1 - drug therapy</topic><topic>Diabetes Mellitus, Type 1 - metabolism</topic><topic>Diabetes. Impaired glucose tolerance</topic><topic>Endocrine pancreas. Apud cells (diseases)</topic><topic>Endocrinopathies</topic><topic>External pump</topic><topic>Female</topic><topic>HDL</topic><topic>Humans</topic><topic>Implantable pump</topic><topic>Infusions, Parenteral</topic><topic>Insulin</topic><topic>Insulin - administration & dosage</topic><topic>Insulin Infusion Systems</topic><topic>Kinetic study</topic><topic>Kinetics</topic><topic>Lipoproteins, HDL - drug effects</topic><topic>Lipoproteins, HDL - metabolism</topic><topic>Male</topic><topic>Medical sciences</topic><topic>Middle Aged</topic><topic>Pharmacology. Drug treatments</topic><topic>Sulfides</topic><topic>Type 1 diabetes mellitus</topic><topic>Vasodilator agents. Cerebral vasodilators</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Duvillard, Laurence</creatorcontrib><creatorcontrib>Florentin, Emmanuel</creatorcontrib><creatorcontrib>Baillot-Rudoni, Sabine</creatorcontrib><creatorcontrib>Lalanne-Mistrich, Marie-Laure</creatorcontrib><creatorcontrib>Brun-Pacaud, Agnès</creatorcontrib><creatorcontrib>Petit, Jean-Michel</creatorcontrib><creatorcontrib>Brun, Jean-Marcel</creatorcontrib><creatorcontrib>Gambert, Philippe</creatorcontrib><creatorcontrib>Vergès, Bruno</creatorcontrib><collection>Pascal-Francis</collection><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>MEDLINE - Academic</collection><jtitle>Atherosclerosis</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Duvillard, Laurence</au><au>Florentin, Emmanuel</au><au>Baillot-Rudoni, Sabine</au><au>Lalanne-Mistrich, Marie-Laure</au><au>Brun-Pacaud, Agnès</au><au>Petit, Jean-Michel</au><au>Brun, Jean-Marcel</au><au>Gambert, Philippe</au><au>Vergès, Bruno</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>No change in apolipoprotein AI metabolism when subcutaneous insulin infusion is replaced by intraperitoneal insulin infusion in type 1 diabetic patients</atitle><jtitle>Atherosclerosis</jtitle><addtitle>Atherosclerosis</addtitle><date>2007-10-01</date><risdate>2007</risdate><volume>194</volume><issue>2</issue><spage>342</spage><epage>347</epage><pages>342-347</pages><issn>0021-9150</issn><eissn>1879-1484</eissn><abstract>Abstract In type 1 diabetic patients, the replacement of subcutaneous insulin infusion by intraperitoneal insulin infusion restores the normal physiological gradient between the portal vein and the peripheral circulation, which is likely to modify HDL metabolism. This stable isotope kinetic study was designed to compare HDL apolipoprotein (apo) AI metabolism in seven type 1 diabetic patients first treated by continuous subcutaneous insulin infusion by an external pump and then 3 months after the beginning of intraperitoneal insulin infusion by an implantable pump. Glycaemic control was comparable under subcutaneous and intraperitoneal insulin infusion (HbA1c = 7.34 ± 0.94% versus 7.24 ± 1.00%, NS). HDL composition was similar under both insulin regimens (esterified cholesterol = 20.1 ± 2.5% versus 24.0 ± 3.0% (NS), free cholesterol = 3.4 ± 1.1% versus 3.3 ± 0.9% (NS), triglycerides = 2.4 ± 0.9% versus 2.1 ± 0.9% (NS), phospholipids = 22.7 ± 5.3% versus 25.2 ± 6.5% (NS) and proteins = 51.2 ± 6.3% versus 45.5 ± 4.7% (NS)). The replacement of subcutaneous insulin infusion by intraperitoneal insulin infusion induced significant changes neither in apoAI fractional catabolic rate, nor in apoAI production rate, nor in apoAI pool size (respectively, 0.199 ± 0.051 pool d−1 versus 0.211 ± 0.017 pool d−1 , 12.0 ± 3.2 mg kg−1 d−1 versus 12.1 ± 1.8 mg kg−1 d−1 , 60.4 ± 5.0 mg kg−1 versus 57.5 ± 7.5 mg kg−1 ). In conclusion, HDL metabolism is not modified by the replacement of subcutaneous insulin infusion by intraperitoneal insulin infusion when glycaemia is well controlled under both insulin regimens. As far as HDL metabolism is concerned there is no advantage in favour of one way of insulin administration or another.</abstract><cop>Amsterdam</cop><pub>Elsevier Ireland Ltd</pub><pmid>17141785</pmid><doi>10.1016/j.atherosclerosis.2006.10.034</doi><tpages>6</tpages></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 0021-9150 |
| ispartof | Atherosclerosis, 2007-10, Vol.194 (2), p.342-347 |
| issn | 0021-9150 1879-1484 |
| language | eng |
| recordid | cdi_proquest_miscellaneous_68424364 |
| source | MEDLINE; Elsevier ScienceDirect Journals |
| subjects | Administration, Cutaneous Adult Apolipoprotein A-I - drug effects Apolipoprotein A-I - metabolism Apolipoprotein AI Associated diseases and complications Atherosclerosis (general aspects, experimental research) Biological and medical sciences Blood and lymphatic vessels Carbon Compounds, Inorganic Cardiology. Vascular system Cardiovascular Cardiovascular system Diabetes Mellitus, Type 1 - drug therapy Diabetes Mellitus, Type 1 - metabolism Diabetes. Impaired glucose tolerance Endocrine pancreas. Apud cells (diseases) Endocrinopathies External pump Female HDL Humans Implantable pump Infusions, Parenteral Insulin Insulin - administration & dosage Insulin Infusion Systems Kinetic study Kinetics Lipoproteins, HDL - drug effects Lipoproteins, HDL - metabolism Male Medical sciences Middle Aged Pharmacology. Drug treatments Sulfides Type 1 diabetes mellitus Vasodilator agents. Cerebral vasodilators |
| title | No change in apolipoprotein AI metabolism when subcutaneous insulin infusion is replaced by intraperitoneal insulin infusion in type 1 diabetic patients |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-23T18%3A06%3A11IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=No%20change%20in%20apolipoprotein%20AI%20metabolism%20when%20subcutaneous%20insulin%20infusion%20is%20replaced%20by%20intraperitoneal%20insulin%20infusion%20in%20type%201%20diabetic%20patients&rft.jtitle=Atherosclerosis&rft.au=Duvillard,%20Laurence&rft.date=2007-10-01&rft.volume=194&rft.issue=2&rft.spage=342&rft.epage=347&rft.pages=342-347&rft.issn=0021-9150&rft.eissn=1879-1484&rft_id=info:doi/10.1016/j.atherosclerosis.2006.10.034&rft_dat=%3Cproquest_cross%3E68424364%3C/proquest_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=68424364&rft_id=info:pmid/17141785&rft_els_id=S002191500600671X&rfr_iscdi=true |